Home›Stocks›AMLX

AMLX — structural market context

Amylyx Pharmaceuticals, Inc. C

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 21. Each line shows the earlier value, the later value and their dates.

Price

Close $29.03 (Oct 21) vs $28.77 (Oct 20): +0.90%.

Volume

1.20× its 20-session average (1.4M) on Oct 21.

Includes pre- and post-market trading.

Short interest

Short interest 12.7M shares (settlement Sep 30) vs 13.5M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 66 shares on Sep 21.

Previous file (settlements Sep 1–Sep 14, published Sep 30): no fails listed.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

AMLX short interest & days to cover

SHARES SHORT
12.7M
% OF FLOAT
13.0%
DAYS TO COVER
9.2
CHANGE VS PRIOR
-6.3%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (22d ago)

AMLX fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-21 · 31d66$32.41
2026-08-31 · 52d1$34.74
2026-08-26 · 57d42$37.46

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

AMLX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 11 sales

InsiderTypeSharesValueFiled
MILNE GEORGE M JR · directorSale (S)30K$831K2026-10-07
Bedrosian Camille L · officer: Chief Medical OfficerSale (S)2K$69K2026-09-14
FRATES JAMES M · officer: Chief Financial OfficerSale (S)10K$315K2026-09-14
FRATES JAMES M · officer: Chief Financial OfficerSale (S)1K$35K2026-09-14
Mazzariello Gina · officer: Chief Legal OfficerSale (S)10K$309K2026-09-14

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

AMLX offering filings (SEC)

2 SEC filings in the last 90 days, by filing date.

FiledFormDocument
2026-08-20Prospectus supplement filed under Rule 424(b)(5) 424B5View on sec.gov ↗
2026-08-18Prospectus supplement filed under Rule 424(b)(5) 424B5View on sec.gov ↗

See all filings on SEC EDGAR ↗

SEC filings listed by filing date. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price. Some of these filings cover debt securities or resales by existing holders. A filing is made by the issuer and appears under each of its tickers. Source: SEC EDGAR daily index; each filing links to its page on sec.gov.

Source: SEC EDGAR daily index, read once a day after the SEC publishes it (around 10:30 pm ET). Forms covered: S-1, S-3, F-1 and F-3 with their amendments, S-3ASR, F-3ASR, 424B4 and 424B5. · as of 2026-10-21

AMLX analyst ratings

FirmActionRatingPublished
CitigroupholdBuy2026-10-15
Guggenheimprice_target—2026-08-27
GuggenheimholdBuy2026-08-19
Guggenheimprice_target—2026-08-19
Mizuho Securitiesprice_target—2026-08-18

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is AMLX's short interest?
As of the FINRA settlement date 2026-09-30, AMLX had 12.7M shares sold short — 13.0% of its float, with 9.2 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying AMLX?
In the last 12 months of SEC Form 4 filings, AMLX recorded 0 insider purchases and 11 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What are the SEC offering filings listed for AMLX?
They are registration statements (Forms S-1, S-3, F-1 and F-3, with their amendments and the S-3ASR and F-3ASR automatic shelf forms) and prospectuses filed under Rule 424(b)(4) or 424(b)(5). In the last 90 days the issuer of AMLX filed 2; the most recent was a prospectus supplement filed under Rule 424(b)(5) on 2026-08-20. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price, and some of these filings cover debt securities or resales by existing holders.
What do analysts say about AMLX?
The most recent action: Citigroup hold to Buy on 2026-10-15. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell AMLX?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with A

AA · Alcoa CorporationAADX · Applied Aerospace & Defense, IAAPG · Ascentage Pharma Group InternaAAPL · Apple Inc.AAUC · Allied Gold CorporationAAVMY · ABN AMRO BK N V AMSTERDAM BRHAll A →

AMLX: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.